SCHEMBL15056515

SCHEMBL15056515

CON(C)C(=O)C=Cc1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.51
KEAP1 Q14145 1/20 0.51
HSP90AA1 P07900 2/20 0.50
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ATM Q13315 1/20 0.48
TUBB4A P04350 2/20 0.47
TUBB P07437 2/20 0.47
TUBA3C P0DPH7 2/20 0.47
TUBA1B P68363 2/20 0.47
TUBA4A P68366 2/20 0.47
TUBB4B P68371 2/20 0.47
TUBB3 Q13509 2/20 0.47
TUBB2A Q13885 2/20 0.47
TUBB8 Q3ZCM7 2/20 0.47
TUBA3E Q6PEY2 2/20 0.47
TUBA1A Q71U36 2/20 0.47
TUBA1C Q9BQE3 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15056513 1.00 NFE2L2 (0.51) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL210591 0.86 KEAP1 (0.53) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL24150010 0.86 KEAP1 (0.53) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL643378 0.79 HSP90AA1 (0.53) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL643379 0.79 HSP90AA1 (0.53) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL24149768 0.79 APP (0.38) NFE2L2KEAP1PADI4APPCYP1B1
SCHEMBL17157735 0.78 ALDH1A1 (0.40) NFE2L2KEAP1HSP90AA1NPC1RAB9A
SCHEMBL17157734 0.78 ALDH1A1 (0.40) NFE2L2KEAP1HSP90AA1NPC1RAB9A
Hydrochloric Acid SCHEMBL2774907 0.78 HSP90AA1 (0.51) NFE2L2KEAP1HSP90AA1NPC1RAB9A
Hydrochloric Acid SCHEMBL2774905 0.78 HSP90AA1 (0.51) NFE2L2KEAP1HSP90AA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794563-B1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2017-02-22 EP disclosed
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 NFE2L2 664/4885KEAP1 2356/4885HSP90AA1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.